ResearcherOsaka International Cancer InstituteActive in the last 2 years
Yasuharu Kawamoto
Matched on ORCID iD 0009-0009-1266-6313. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2022: 2 papers · 2023: 2 papers · 2024: 2 papers
Papers 6
- Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-024-73020-8↗
- Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer. Co-author DOI 10.1186/s12885-024-12722-8↗
- Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. Co-author DOI 10.1007/s00432-023-04966-x↗
- Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer. Co-author DOI 10.1186/s12885-023-11205-6↗
- Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic ca… Co-author DOI 10.1371/journal.pone.0264653↗
- 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine an… Co-author DOI 10.3390/curroncol29040216↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kenji Ikezawa · 6 shared papers, 2022–2024 · strength 0.92
- Paper Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1038/s41598-024-73020-8↗
- Paper Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy… DOI 10.1186/s12885-024-12722-8↗
- Paper Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. DOI 10.1007/s00432-023-04966-x↗
- Takuo Yamai · 6 shared papers, 2022–2024 · strength 0.92
- Paper Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1038/s41598-024-73020-8↗
- Paper Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy… DOI 10.1186/s12885-024-12722-8↗
- Paper Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. DOI 10.1007/s00432-023-04966-x↗
- Ryoji Takada · 6 shared papers, 2022–2024 · strength 0.92
- Paper Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1038/s41598-024-73020-8↗
- Paper Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy… DOI 10.1186/s12885-024-12722-8↗
- Paper Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. DOI 10.1007/s00432-023-04966-x↗
- Yugo Kai · 6 shared papers, 2022–2024 · strength 0.92
- Paper Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1038/s41598-024-73020-8↗
- Paper Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy… DOI 10.1186/s12885-024-12722-8↗
- Paper Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. DOI 10.1007/s00432-023-04966-x↗
- Makiko Urabe · 6 shared papers, 2022–2024 · strength 0.92
- Paper Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1038/s41598-024-73020-8↗
- Paper Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy… DOI 10.1186/s12885-024-12722-8↗
- Paper Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. DOI 10.1007/s00432-023-04966-x↗
- Kazuyoshi Ohkawa · 6 shared papers, 2022–2024 · strength 0.92
- Paper Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1038/s41598-024-73020-8↗
- Paper Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy… DOI 10.1186/s12885-024-12722-8↗
- Paper Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. DOI 10.1007/s00432-023-04966-x↗
- Ko Watsuji · 4 shared papers, 2023–2024 · strength 0.66
- Paper Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1038/s41598-024-73020-8↗
- Paper Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy… DOI 10.1186/s12885-024-12722-8↗
- Paper Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. DOI 10.1007/s00432-023-04966-x↗
- Yusuke Seiki · 4 shared papers, 2023–2024 · strength 0.66
- Paper Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. DOI 10.1038/s41598-024-73020-8↗
- Paper Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy… DOI 10.1186/s12885-024-12722-8↗
- Paper Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. DOI 10.1007/s00432-023-04966-x↗
- Kazuma Daiku · 2 shared papers, 2022 · strength 0.26
- Paper 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pa… DOI 10.3390/curroncol29040216↗
- Paper Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients wi… DOI 10.1371/journal.pone.0264653↗
- Shigenori Nagata · 1 shared paper, 2024 · strength 0.18
- Nobuyasu Fukutake · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.